High prevalence of treatable transthyretin cardiac amyloidosis in cardioembolic stroke: the first systematic cohort study. Harada S, Nakajima M, Nomura T, Kimura R, et al. J Neurol 2026;273:86.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Harada S, Nakajima M, Nomura T, Kimura R, et al. High prevalence of treatable transthyretin cardiac amyloidosis in cardioembolic stroke: the first systematic cohort study. J Neurol 2026;273:86.
PMID: 41553541